Tag: convalescent plasma

1. Majority of the patients that received high-titer convalescent plasma within 72 hours of mild symptom onset were shown to reduce the coronavirus disease 2019 (COVID-19) severe illness progression. 2. The IgG titer distribution between the treatment group and placebo group revealed a significant difference. Evidence Rating Level: 1 (Excellent) Study Rundown:...
1. Patients aged 65 years or greater who received convalescent plasma within 72 hours of symptom onset were less likely to develop severe respiratory disease compared to those who received placebo. 2. These benefits appeared to be dose-dependent, with higher donor antibody concentrations conferring greater protection upon the recipients. Evidence Rating...
1. Convalescent plasma did not improve clinical outcomes in patients with severe pneumonia due to coronavirus disease 2019 (Covid-19) compared to placebo. 2. Convalescent plasma did not reduce 30-day mortality in patients with Covid-19 compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: The treatment of convalescent plasma is guided by...
1. In this small, uncontrolled, non-randomized case series, clinical improvement was noted in 5 critically ill patients with COVID-19 and ARDS following treatment with convalescent plasma. Evidence Rating: 4 (Below Average) With no specific therapeutic agents or vaccines available for COVID-19, ongoing efforts are being made to identify a treatment option...
1. In this small, uncontrolled, non-randomized case series, clinical improvement was noted in 5 critically ill patients with COVID-19 and ARDS following treatment with convalescent plasma. Evidence Rating: 4 (Below Average) With no specific therapeutic agents or vaccines available for COVID-19, ongoing efforts are being made to identify a treatment option...